Table 1.
The characteristics of the included studies
| Study No. | Year | First Author | Country | Prescribed dose (Gy) | Sample Size | OAR (Level of the Dose) (Gy) | MUs | Delivery Time | ||
|---|---|---|---|---|---|---|---|---|---|---|
| IMRT | VMAT | Rectum | Bladder | |||||||
| 1 | 2009 | Wolff D (12) | Germany | 76 | 9 | 9 | — | — | Yes | Yes |
| 2 | 2011 | Hardcastle N (37) | Australia | 78 | 10 | 10 | — | — | Yes | Yes |
| 3 | 2011 | Fogarty GB (38) | Australia | 74/78 | 8 | 8 | — | — | Yes | — |
| 4 | 2011 | Sale C (21) | Australia | 75.6 | 8 | 8 | V40,V50, V60,V70 | V50,V60, V70 | — | — |
| 5 | 2011 | Tsai CL (13) | Taiwan | 78 | 12 | 12 | V40 | V40 | Yes | Yes |
| 6 | 2012 | Quan EM (20) | USA | 76 | 11 | 11 | V40,V50, V60,V70 | V40,V50, V60,V70 | — | — |
| 7 | 2012 | Nguyen BT (39) | Australia | 68 | 10 | 10 | V50,V60 | V60,V70 | Yes | Yes |
| 8 | 2013 | Elith CA (30) | Australia | 74 | 20 | 20 | V40,V50, V60,V70 | V40,V50, V60,V70 | Yes | Yes |
| 9 | 2014 | Onal C (34) | Turkey | 78 | 12 | 12 | V40,V50, V60,V70 | V40,V60, V70 | Yes | — |
| 10 | 2015 | Cakir A (19) | Turkey | 74 | 10 | 10 | V50,V70 | V50,V70 | Yes | — |